Enzalutamide has previously been shown to induce immunogenic modulation in TRAMP-C2 mouse prostate carcinomas and to improve tumor cells' sensitivity to gp70-specific cytotoxic T-lymphocyte (CTL) killing in vitro [10]. This evidence concerns the gene EMB and neoplasm.